Abstract: There is provided a complex for use as a therapeutic pharmaceutical, the complex has a ligand containing at least one hydroxyalkyl phosphine donor group bound to a gold atom to form a stable gold-ligand complex. Also provided is a method of treating cancer by administering an effective amount of a complex having a ligand of at least one hydroxyalkyl phosphine group bound to a gold atom to form a stable gold-ligand complex. Also provided is a method of preventing the metastasis of cancer and arresting cell growth by administering an effective amount of a complex having a ligand of at least one hydroxyalkyl phosphine group bound to a gold atom to form a stable gold-ligand complex.
Type:
Grant
Filed:
June 23, 2000
Date of Patent:
January 24, 2006
Assignee:
The Curators of the University of Missouri
Inventors:
Kattesh V. Katti, Wynn A. Volkert, Timothy Hoffman
Abstract: Isolated polynucleotide molecules contain a nucleotide sequence that encodes a L. intracellularis HtrA, PonA, HypC, LysS, YcfW, ABC1, or Omp100 protein, a substantial portion of the sequences, or a homologous sequence. Related polypeptides, immunogenic compositions and assays are described.
Abstract: This invention relates to stabilized protein compositions, methods for preparing such stabilized protein compositions, dosage forms for administering such stabilized protein compositions to mammals and methods for preventing or treating infections in mammals by administering such protein compositions to mammals. More particularly, the stabilized protein compositions of the present invention contain therapeutically effective amounts of G-CSF, such as bovine G-CSF, in combination with a stabilizing buffer, such as HEPES, TES or TRICINE, for treating and preventing infections, including mastitis, in cattle.
Type:
Grant
Filed:
August 12, 1999
Date of Patent:
December 27, 2005
Assignees:
Pfizer Inc., Pfizer Products Inc.
Inventors:
Peter C. Canning, Barbara J. Kamicker, Kasra Kasraian
Abstract: A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naïve T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naïve T-cells and exposing the naïve T-cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T-cells to gain immunization of the T-cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions.
Abstract: There is provided an apparatus for screening pharmacological agents for agents which induce regression of cancer. The apparatus includes an evanescent sensing device, at least one sensor having affixed to its surface molecules of a first type, which have affinity for molecules of a biological receptor, the surface molecule and receptor molecule combination having the effect that, in vivo, the binding affects the rate of transcription of gene products, and a molecular tag wherein the molecular tag is bound to the sensor wherein the binding between molecules of the first type and molecules the biological receptor cause the tag to produce a alteration in signal recorded by the evanescent sensing device, the tag also being bound to molecules of a second type, the molecules of the second type having affinity for the receptor molecules.
Type:
Grant
Filed:
July 20, 2001
Date of Patent:
November 8, 2005
Assignee:
The University of Louisville Research Foundation
Inventors:
Judith L. Erb, James G. Downward, IV, John R. Erb-Downward, James L. Witliff
Abstract: The present invention is directed to a releasable locking assembly for attaching a wear member to a support structure. It may be used with excavating equipment for attaching ground-engaging teeth to adaptors, lip shrouds to bucket lips, or other analogous uses. The wear member includes at least one pin-retainer-receiving opening in one side. The opening is tapered, being narrower at its outer surface and wider at its inner surface. The support structure includes at least one pin-receiving recess which generally aligns with the opening in the wear member when the wear member and the support structure are operatively coupled. The pin retainer is a frustoconically shaped cylinder which is threaded internally. It is inserted into the opening in the wear member. The wear member is slidably mounted onto the support structure. The pin is an elongate body which is externally threaded. It is screwed into the pin retainer by the application of torque force from a standard ratchet tool.
Abstract: According to the present invention, there is provided a transverse connector having a seat rod for seating a rod therein engagement mechanism including a rod engagement seat forming a portion of the rod seat, the engagement mechanism being movable into and out of engagement with the rod seated in the rod seat.
Abstract: An adjustable safety mechanism for a motorcycle foot peg, the device including a support mechanism for providing additional support for a foot a mounter for mounting the support mechanism on and spaced from the foot peg, an adjusting mechanism for adjusting the support mechanism relative to the foot peg, the adjusting mechanism extending between the support mechanism and the mounter. A method of retrofitting a safety device on a motorcycle foot peg by mounting the safety device on an attached motorcycle foot peg utilizing a universal bracket.
Abstract: A transverse connector having a seat rod for seating a rod therein engagement mechanism including a rod engagement seat forming a portion of the rod seat, the engagement mechanism being movable into and out of engagement with the rod seated in the rod seat.
Abstract: According to the present invention, there is provided a hose assembly with an inner fluoropolymer layer having a smooth inner surface and an outer polyamide layer having an undulated surface.
Abstract: A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject an effective amount of a radiopharmaceutical having a metal chelated with a chelating group attached to a moiety capable of binding to a gastrin releasing peptide receptor expressed on tumor cells with subsequent internalization inside of the cell. A method of forming a therapeutic or diagnostic compound includes reacting a metal synthon with a chelating group covalently linked with a moiety capable of binding a gastrin releasing peptide receptor.
Type:
Grant
Filed:
April 12, 2002
Date of Patent:
July 26, 2005
Assignee:
Curators of the University of Missouri
Inventors:
Timothy J. Hoffman, Wynn A. Volkert, Ning Li, Gary Sieckman, Chrys-Ann Higginbotham
Abstract: The present invention is directed to a method of producing attenuated forms of bovine viral diarrhea (BVD) virus by mutating the Npro protease gene. The invention includes the attenuated viruses made by this method, antibodies generated using these viruses, and vaccines that can be used for immunizing cattle.
Abstract: The subject invention provides a fusion protein for producing a dual immune response in a vertebrate, which fusion protein comprises: (a) a first proteinaceous portion analogous to all or part of a peptide endogenously synthesized within the vertebrate, the activity of which peptide is to be inhibited within the vertebrate, and which proteinaceous portion by itself is incapable of eliciting an effective immunoinhibitory response in said vertebrate; connected to (b) a second proteinaceous portion analogous to all or part of an immunogen from a pathogen, which pathogen is capable of pathogenically infecting the vertebrate; the portion (b) causing the vertebrate's immune system to recognize the portion (a) and produce a response that: (i) inhibits the activity of the peptide endogenously synthesized within the vertebrate; and (ii) protects the vertebrate from infection by the pathogen, when the vertebrate is vaccinated with an effective amount of the fusion protein.
Type:
Grant
Filed:
February 16, 2000
Date of Patent:
June 28, 2005
Assignees:
Pfizer Inc., Pfizer Products Inc.
Inventors:
Manuel Campos, Terecita D. Yule, Serge Martinod, Becky A. Durtschi
Abstract: The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of an IgE molecule as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions, methods for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides derived from the CH3 domain or junction of Ch-3/CH4 domain of an IgE molecule and methods for the evaluation of IgE mediated allergies in dogs.
Type:
Grant
Filed:
August 24, 2001
Date of Patent:
May 3, 2005
Assignees:
Pfizer Inc., Pfizer Products Inc.
Inventors:
Mohamad A. Morsey, Michael G. Sheppard, David W. Wheeler
Abstract: The present invention provides for a method of evolving and selecting cells resistant to a selective agent by inducing directed evolution in continuous culture while applying both a mutagenic and selective agent to the cells to determine the cells having resistance. This also provides a method of generating mutant drug targets useful for screening for effective compounds.
Abstract: A particulate matter propulsion apparatus (10) for propelling confetti (94) or similar from a greeting card (12). The propulsion device includes a particulate matter receptacle (14) attached to a supporting means (16), the supporting means (16) being store energy such that when the card (12) is opened the particulate matter (94) is propelled from the card (12).
Abstract: Container moving apparatus (10) including a frame having two side members (12, 14), which are connected at an upper location by a handle section (16). Each side member has a clamping member (20, 22) secured at a lower position. The clamping members (20, 22) are secured to the side members (12, 14) through roller bearings (24, 26) in order for the clamping members (20, 22) to rotate relative to the side members (12, 14). The clamping members (20, 22) are arranged to clamp a container (32) therebetween in order for the container (32) to be rolled along a surface under the control of the handle section (10). The clamping members (20, 22) can be moved apart in order to release the container (32) and move towards each other in order to claim the container (32).
Abstract: The present invention relates generally to therapeutic compositions for the treatment and/or prophylaxis of intestinal disease conditions in animals and birds caused or exacerbated by Lawsonia intracellularis or similar or otherwise related microorganism. In particular, the present invention provides a novel gene derived from Lawsonia intracellularis, which encodes an immunogenic polypeptide that is particularly useful as an antigen in a vaccine preparation for conferring humoral immunity against Lawsonia intracellularis and related pathogens in animal hosts, wherein said polypeptide is selected from the group consisting of flhB, fliR, ntrC, glnH, motA, motB, tlyC, ytfM, and ytfN polypeptides, or a homologue, analogue or derivative of any one or more of said polypeptides.
Abstract: A non-food anti-microbial-adhesion and aggregation composition comprising a suitable carrier and an effective amount of an adhesion inhibitory fraction isolated from juice from berries of the Vaccinium plant genus. In an embodiment the anti-aggregation and adhesion fraction is isolated from cranberry juice. It is characterized as being polymeric and having a molecular weight ?14,000; an elemental analysis of carbon 43-51%, hydrogen 4-5%, no nitrogen, no sulfur and no chlorine; a nuclear magnetic resonance (NMR) line spectrum as set forth in FIGS. 2A and 2B; and an ultraviolet spectrum with an absorption peak at 280 nm in neutral or acidic pH solution which is absent in alkali solutions. This fraction exhibits adhesion inhibitory activity against P fimbriated bacteria, oral bacteria and Helicobacter pylori.
Abstract: The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal.
Type:
Grant
Filed:
March 13, 2003
Date of Patent:
November 9, 2004
Assignee:
Pfizer Inc.
Inventors:
David S. Roberts, Leroy A. Swearingin, Don A. Dearwester